StrataMGT in the Reduction of Vulvar Lichen Sclerosus (LS) Symptoms

Description

This study is designed to evaluate the efficacy and safety of StrataMGT for the management of vulvar lichen sclerosus symptoms.

Conditions

Vulvar Lichen Sclerosus

Study Overview

Study Details

Study overview

This study is designed to evaluate the efficacy and safety of StrataMGT for the management of vulvar lichen sclerosus symptoms.

A Double Blind Placebo-controlled Trial of StrataMGT for the Management of Vulvar Lichen Sclerosus Symptoms.

StrataMGT in the Reduction of Vulvar Lichen Sclerosus (LS) Symptoms

Condition
Vulvar Lichen Sclerosus
Intervention / Treatment

-

Contacts and Locations

Washington

Centers for Vulvovaginal Disorders, DC, Washington, District of Columbia, United States, 20037

Tampa

Centers for Vulvovaginal Disorders, FL, Tampa, Florida, United States, 33609

New York

Centers for Vulvovaginal Disorders, NY, New York, New York, United States, 10036

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Female, 18 years or older.
  • * With a diagnosis of biopsy proven vulvar lichen sclerosus.
  • * Signed written informed consent.
  • * Willingness and ability to comply with the study requirements.
  • * Subject must have a score of 10 or greater in the VQLI at screening.
  • * Must be on a stable regimen of topical corticosteroids or topical calcineurin inhibitor for at least 2 months prior to the screening visit.
  • * Women currently on a stable regimen of intravaginal estrogen therapy for at least 2 months may remain on the estrogen therapy throughout the study.
  • * Women currently using topical estrogen therapy on the vulva must stop two weeks prior to enrolling in the study.
  • * Women must have a culture negative for candidiasis or bacterial vaginosis at screening.
  • * Who are immunocompromised (e.g., lymphoma, AIDS, Wiskott-Aldrich Syndrome) or have an uncontrolled malignant disease.
  • * Who suffer from a topical or systemic infections (bacterial, viral or fungal) at the time of screening. Subjects who screen positive for either candidiasis or bacterial vaginosis at the screening visit may be treated and retested and may participate if the confirmatory test after treatment is negative. Any vulvovaginal infections during their participation in the study will be considered an adverse event. The subject will then stop the study IP and will be treated for the infection and may resume use of the IP 3 days after the last dose of medication for the infection. They will be discontinued from the study if they have two infections during the study.
  • * Who have been diagnosed with lichen planus, psoriasis, intraepithelial neoplasia, or carcinoma of the vulva.
  • * Who had received an investigational drug within four weeks prior to the study or who intend to use other investigational drugs during the course of this study.
  • * Patients with severe medical condition(s) that in the view of the investigator prohibits participation in the study.
  • * Who have a history of substance abuse or any factor, which limits the subject's ability to cooperate with the study procedures.
  • * Who are uncooperative, known to miss appointments (according to subjects' records) and are unlikely to follow medical instructions or are not willing to attend regularly scheduled visits.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

Andrew T. Goldstein, MD,

Chailee Moss, MD, STUDY_DIRECTOR, Centers for Vulvovaginal Disorders, DC

Jill Krapf, MD, STUDY_DIRECTOR, Centers for Vulvovaginal Disorders, FL

Study Record Dates

2025-10-16